Mannkind Corp Dossier
Qualitative Analysis
Business overview
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company focused on developing and commercializing inhaled therapeutic products and devices to address serious unmet medical needs for patients living with endocrine and orphan lung diseases. The company's signature technologies include its Technosphere dry-powder formulation technology and Dreamboat inhalation devices, which enable rapid and convenient delivery of medicines to the deep lung. MannKind's commercial portfolio is anchored by Afrezza (insulin human) Inhalation Powder, the only inhaled ultra-rapid-acting mealtime insulin in the United States, and Furoscix (furosemide injection), an FDA-approved subcutaneous formulation for fluid overload in heart failure. Additionally, the company generates significant royalty revenues from its collaboration with United Therapeutics Corporation for Tyvaso DPI (treprostinil inhalation powder).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Commercializing and educating pediatric endocrinologists on the newly approved Afrezza inhaled insulin for children and adolescents aged 6 and older.
Expected impact: Provides a needle-free mealtime insulin option to over 350,000 pediatric diabetes patients in the US, driving long-term adoption.
Advancing the clinical development of Nintedanib DPI using MannKind's proprietary Technosphere platform to treat Idiopathic Pulmonary Fibrosis (IPF).
Expected impact: Bypasses the GI tract to improve tolerability and efficacy compared to oral therapies, addressing a major unmet need in IPF.
Partnering with Cipla to launch and commercialize Afrezza in India.
Expected impact: Expands the global footprint of inhaled insulin into one of the world's largest diabetes markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire FUROSCIX, an FDA-approved subcutaneous furosemide infusion therapy, establishing a strategic entry into cardiorenal medicine and diversifying the cardiometabolic portfolio.
Financial impact: Diversifies revenue streams, adding FUROSCIX net sales (which reached $23 million in Q4 2025) and contributing to an annualized combined run rate exceeding $370 million.
Strategic Partnerships
Co-developing dry powder inhalation formulations (such as Tyvaso DPI, MNKD-1501, and MNKD-201) using MannKind's Technosphere platform, providing MannKind with a 9% royalty stream on Tyvaso DPI net sales.
Terms: MannKind receives a 9% royalty on net sales of Tyvaso DPI and is eligible for up to $35 million in milestone payments for additional pipeline molecules.
Cipla leads the regulatory approval, distribution, and commercialization of Afrezza in India, leveraging its extensive local market presence.
Terms: Cipla is responsible for commercialization in India, with MannKind supplying the product.